Industry News
Pharmaceutical Industry News
Neurocrine Biosciences has shared…
Neurocrine Biosciences has shared survey data showing how tardive dyskinesia affects the ability of patients and caregivers to work, supporting the company’s case for timely treatment of the movement disorder.
Kyverna Therapeutics is on the…
Kyverna Therapeutics is on the cusp of a historic first: getting a CAR-T therapy approved for an autoimmune disease—and now it’s looking to boost its commercial chops as it nears the finish line.
Created from the merger of…
Created from the merger of Mallinckrodt and Endo last year, Keenova is launching its first Dupuytren's contracture campaign under its new moniker.
Kennedy Starts a Push to Help Americans Quit Antidepressants
The health secretary has long complained that Americans overuse psychiatric medications. New policies he is introducing aim to change that.
Cytokinetics has aced a phase 3…
Cytokinetics has aced a phase 3 trial of Myqorzo in patients with non-obstructive hypertrophic cardiomyopathy. The South San Francisco company is bidding to make Myqorzo the first treatment approved in the indication.
Though largely operating in the…
Though largely operating in the background until recently, Prolific Machines’ optogenetic approach to biomanufacturing is set to make waves thanks to the achievement of an impressive milestone in monoclonal antibody manufacturing.
The U.S. Supreme Court has…
The U.S. Supreme Court has temporarily reinstated online access to the abortion pill mifepristone after a federal appeals court in New Orleans ruled to prevent mifepristone from being prescribed over the phone and sent through
The company chalks up a financial…
The company chalks up a financial impact of about 150 billion Korean won ($102 million) from "preemptive production adjustments" made to mitigate potential manufacturing impacts, a spokesperson said.
After submitting plans to cut 114…
After submitting plans to cut 114 jobs tied to its U.S. headquarters in New Jersey in March, Novartis late last month added a handful of additional roles from the East Hanover site to its multiyear
Bristol Myers Squibb is warming up…
Bristol Myers Squibb is warming up for the FIFA World Cup 2026 with a new media campaign, launching its “Won’t Lose” ad ahead of the soccer community arriving in the U.S. for this summer’s tournament.
After topping up its long-running…
After topping up its long-running operations in Puerto Rico last year, Amgen is infusing $300 million more into the U.S. territory.
A Long, Strange Trip: How the G.O.P. Came to Embrace Psychedelic Drugs
For decades, conservatives were adamantly opposed to the use of drugs like psilocybin and LSD. Now, the Trump administration has made a sharp pivot.
Supreme Court Asked to Restore Access to Abortion Pill by Mail
A federal appeals court temporarily halted a Food and Drug Administration regulation that has greatly expanded access to the abortion pill mifepristone.
F.D.A. Grants Early Access to Promising Drug for Pancreatic Cancer
Patients with one of the deadliest cancers have been pleading for an unapproved treatment that may prolong their lives.
The early FDA approval doesn’t…
The early FDA approval doesn't change Pfizer and Arvinas' plan to leave commercialization of the drug to a yet-to-be-identified partner.
Top Psychiatrists Call for a Greater Focus on Ceasing Medication
With Health Secretary Robert F. Kennedy Jr. aiming to rein in the use of psychiatric drugs, psychiatrists are preemptively addressing how and when patients should quit taking them.
Four years after gaining FDA…
Four years after gaining FDA approval for Auvelity to treat major depressive disorder, Axsome Therapeutics has tacked on a second nod in the United States for the first-in-class medicine to treat agitation associated with Alzheimer’s
Shortly after laying out $75…
Shortly after laying out $75 million upfront for Corstasis Therapeutics and its congestive heart failure edema drug Enbumyst, Esperion Therapeutics is itself being acquired and taken private by healthcare investment firm ArchMmed.
The company looks to achieve an…
The company looks to achieve an "amicable resolution as soon as possible" and is focused on minimizing disruption to its operations, a spokesperson said in an emailed statement.
A surprise interim trial miss in…
A surprise interim trial miss in ivonescimab’s closely watched Harmoni-3 trial has sent Summit Therapeutics’ shares tumbling, casting a shadow over the company’s momentum as the star PD-1xVEGF bispecific heads into the ASCO annual meeting